There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

Danish offshore wind giant Orsted faced a fresh stock market hammering on Tuesday after the group announced a new ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Europe’s Stoxx 600 index hit a record high for the first time since September, as investors grew optimistic that the harshest ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The Stoxx Europe 600 hit a record high on Wednesday, in the latest sign of bullish sentiment among global investors. The broad-based European index rose 0.6 per cent to 529.14, led by stocks in the ...

The pan-European STOXX 600 was up 0.5%, as of 0822 GMT, and trading at its highest level since Sept. 27, 2024. Heavyweight ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...